Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rodgers, Barbara A
NCT06052293: Phase 1 Study to Assess Safety and Efficacy of ANG003	Completed	1	51	US	ANG003, Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4.	Anagram Therapeutics, Inc.	Exocrine Pancreatic Insufficiency	07/24	07/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rodgers, Barbara A
NCT06052293: Phase 1 Study to Assess Safety and Efficacy of ANG003	Completed	1	51	US	ANG003, Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4.	Anagram Therapeutics, Inc.	Exocrine Pancreatic Insufficiency	07/24	07/24